Researchers at ETH Zurich, led by molecular pharmacologist Ursula Quitterer, report that an inactive, clumping form of the enzyme GRK2 accumulates in brain tissue from people who had dementia likely due to Alzheimer's disease and in mice bred to develop Alzheimer's-like pathology, according to a study published online March 26, 2026 in Cell Reports Medicine. The team, whose work began nearly two decades ago with tissue samples from a hospital in Cairo, found that this aggregated form of GRK2, marked by a specific chemical modification called phosphorylation at a site named serine-670, attaches to mitochondria, the structures that supply cells with energy, and appears to impair their function while also promoting production of amyloid-beta, the protein fragment long associated with Alzheimer's disease.

To test whether disrupting this aggregation could change outcomes, the researchers synthesized and screened several chemical agents in cell cultures and in mice, identifying one, referred to as Compound 10, that prevented GRK2 molecules from clumping together. In treated mice, the researchers report better mitochondrial function, reduced amyloid-beta accumulation in brain tissue, slower loss of nerve cells, and longer survival compared with untreated mice from the same Alzheimer's model. The authors describe the mechanism as distinct from the amyloid- and tau-clearing approaches used by currently approved Alzheimer's drugs, which the team notes can, at best, delay symptom progression by months.

The findings remain confined to laboratory and animal work. Compound 10 has not been tested in humans, and the authors and outside coverage of the study note that further research, including safety and toxicology work, is required before any human trial could begin. Quitterer and ETH Zurich have applied for a patent on the compound and are seeking a company to pursue further development, a step that is itself an acknowledgment that the work sits far upstream of any treatment reaching patients.